Celmatix

The firm recently won $4.5 million as well as approval for its Fertilome test from New York state, though some have questioned the test's clinical utility.

The award is one of 121 for projects in New York City this year, totaling $64.8 million.

The firm has secured NYS approval for its sequencing-based 32-gene Fertilome assay, which it originally launched in January. 

The companies will recruit and track a cohort of women to study environmental, genetic, and lifestyle factors that may contribute to fertility outcomes.

Fertility Genetics

Celmatix's Fertilome test aims to give women genetic insight into their fertility.

The company's new blood-based test is the first clinical test offering that the company will be offering at its New York-based CLIA laboratory.

They will work to accelerate the launch of Celmatix's infertility genetics tests and develop early screening tests for declining ovarian function.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.